Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors
The Portnoy Law Firm has announced a class action lawsuit on behalf of investors in REGENXBIO, Inc. (NASDAQ: RGNX). The lawsuit covers investors who purchased securities between February 9, 2022, and January 27, 2026, alleging that the company made false and misleading statements regarding its RGX-111 trial study. The suit claims REGENXBIO concealed material adverse facts, specifically that a clinical hold was placed on RGX-111 due to a CNS tumor found in a participant, which led to an 18% stock drop.
RGNX Shareholder Alert: April 14, 2026 Lead Plaintiff Deadline in REGENXBIO Inc. Securities Class Action Lawsuit -- The Gross Law Firm
The Gross Law Firm has issued a shareholder alert regarding a securities class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX). Shareholders who purchased RGNX shares between February 9, 2022, and January 27, 2026, are encouraged to contact the firm, as there is a lead plaintiff deadline of April 14, 2026. The lawsuit alleges that REGENXBIO made misleading statements about its product candidate RGX-111, leading to a significant stock price drop after the FDA placed a clinical hold on the therapy.
Book value per share of REGENXBIO, Inc. – SWB:RB0
This article focuses on the book value per share of REGENXBIO, Inc. (SWB:RB0) as provided by TradingView. It briefly mentions the company's financial data available on the platform without providing specific values or detailed financial analysis. The page is primarily a portal for financial information and market data for the stock.
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX) and its officers, alleging violations of federal securities laws. The lawsuit claims that REGENXBIO made materially false and misleading statements regarding its RGX‑111 gene therapy for Hurler syndrome. Investors who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026, are encouraged to join the case, with a lead plaintiff deadline of April 14, 2026.
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm has announced a class action lawsuit against REGENXBIO Inc. (RGNX) for alleged securities fraud, citing that the company made misleading statements about its product candidate RGX-111 while concealing negative efficacy and safety data. Investors who purchased RGNX securities between February 9, 2022, and January 27, 2026, are encouraged to contact the firm to participate before the April 14, 2026 deadline. The lawsuit claims investors suffered damages when the truth about Regenxbio's statements became known.
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages REGENXBIO, Inc.
The Rosen Law Firm is encouraging investors of REGENXBIO, Inc. (NASDAQ: RGNX) to secure legal counsel before the April 14, 2026, lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that REGENXBIO made false and misleading statements regarding the efficacy and safety of its RGX-111 gene therapy trial. Investors who purchased RGNX securities between February 9, 2022, and January 27, 2026, may be entitled to compensation.
CapEx per share of REGENXBIO, Inc. – SWB:RB0
The article focuses on the "CapEx per share" financial metric for REGENXBIO, Inc. (SWB:RB0), listed on the Stuttgart Stock Exchange. It provides an overview of the company's financial data, accessible through the TradingView platform. The content primarily highlights the availability of this specific financial information to investors.
Tangible book value per share of REGENXBIO, Inc. – SWB:RB0
This article focuses on the "Tangible book value per share" for REGENXBIO, Inc. (SWB:RB0), an American biotechnology company. The content appears to be a financial data page from TradingView, indicating that the market was closed at the time of viewing. It lists the company's ticker on the Stuttgart Stock Exchange and provides a brief overview of available financial information.
ROSEN, SKILLED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before ...
The Rosen Law Firm is encouraging investors of REGENXBIO, Inc. (NASDAQ: RGNX) who purchased securities between February 9, 2022, and January 27, 2026, to secure legal counsel before the April 14, 2026, lead plaintiff deadline. The firm highlights its experience in securities class action litigation and notes that a class action lawsuit has already been filed, alleging that REGENXBIO made misleading statements about its product candidate RGX-111. Investors are advised that their ability to share in any future recovery is not dependent on serving as lead plaintiff.
RGNX PE Ratio & Valuation, Is RGNX Overvalued
Regenxbio Inc (RGNX) is currently considered undervalued, with its forward P/S ratio of 1.46 being lower than its five-year average. The fair price for RGNX is estimated to be between $30.73 and $63.79, indicating it is approximately 72.24% undervalued compared to its current price of $8.53. Despite a higher current Price-to-Book ratio, its P/S ratio of 1.44 is significantly below the industry average, which is deemed sustainable given its robust revenue growth of 43.00%.
RGNX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
Faruqi & Faruqi, LLP is reminding REGENXBIO (RGNX) investors that the deadline to seek the role of lead plaintiff in a federal securities class action is April 14, 2026. The lawsuit alleges that REGENXBIO and its executives made false or misleading statements by failing to disclose material adverse facts regarding the efficacy and safety of its RGX-111 trial study, which led to a clinical hold by the FDA on RGX-111 and RGX-121 following a neoplasm in a study participant. Investors who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026, and suffered losses are encouraged to contact the firm.
REGENXBIO, Inc. Class Action Reminder - Robbins LLP Encourages RGNX Stockholders to Contact the Firm for Information About Their Rights
Robbins LLP is reminding REGENXBIO, Inc. (NASDAQ: RGNX) stockholders about a class action lawsuit filed on behalf of investors who purchased securities between February 9, 2022, and January 27, 2026. The lawsuit alleges that REGENXBIO misled investors about the viability of its drug candidate RGX-111, which was later placed on clinical hold by the FDA due to safety concerns, leading to a significant stock price decline. Shareholders have until April 14, 2026, to submit papers to the court to serve as lead plaintiff.
REGENXBIO (RGNX) proxy: directors, PwC ratification, option-exchange votes
REGENXBIO Inc. is holding its Annual Meeting on May 29, 2026, where shareholders will vote on the election of three Class II directors, the ratification of PwC as the independent auditor, an advisory "say-on-pay" vote for executive compensation, and two proposals regarding stock option exchanges for both non-executive and executive employees. The company highlights its 2025 progress, including clinical trial enrollments, a strategic partnership with Nippon Shinyaku, and a royalty bond agreement, while also disclosing regulatory setbacks for its RGX-121 program. These option exchange programs are proposed to retain talent and realign employee incentives given the significant number of "underwater" stock options due to stock price declines.
REGENXBIO, Inc. Class Action Reminder - Robbins LLP Encourages RGNX Stockholders to Contact the Firm for Information About Their Rights
Robbins LLP is reminding stockholders of REGENXBIO, Inc. (NASDAQ: RGNX) about a class action lawsuit filed on behalf of investors who purchased securities between February 9, 2022, and January 27, 2026. The lawsuit alleges that REGENXBIO misled investors regarding the viability of its gene therapy drug candidate, RGX-111, which was later placed on clinical hold by the FDA due to safety concerns, causing a significant stock price decline. Shareholders are encouraged to contact Robbins LLP for information about their rights and to potentially serve as lead plaintiff.
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against REGENXBIO Inc. (NASDAQ:RGNX) and its officers. The lawsuit alleges that REGENXBIO made false and misleading statements regarding the development and commercialization of its gene therapy, RGX‑111, for Hurler syndrome. Shareholders who purchased RGNX securities between February 9, 2022, and January 27, 2026, have until April 14, 2026, to request to be appointed as lead plaintiff.
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is reminding investors of a class action lawsuit against REGENXBIO Inc. (RGNX) for alleged securities fraud. The lawsuit claims that Regenxbio made false and misleading statements about the efficacy and safety of its product candidate RGX-111, concealing negative data, particularly after an intraventricular CNS tumor was discovered in a study participant. Investors who purchased RGNX securities between February 9, 2022, and January 27, 2026, are encouraged to contact the firm before April 14, 2026, to participate in the lawsuit seeking to recover losses.
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX), alleging that the company made materially false and misleading statements regarding its RGX-111 gene therapy for Hurler syndrome. Investors who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026, are encouraged to join the lawsuit, with a lead plaintiff deadline of April 14, 2026. The firm represents investors on a contingency fee basis, aiming to recover damages for alleged violations of federal securities laws.
RGNX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against REGENXBIO Inc. (NASDAQ:RGNX) and its officers. The lawsuit alleges that REGENXBIO made false and misleading statements regarding its RGX-111 gene therapy for Hurler syndrome, overstating its efficacy and safety. Investors who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026, and suffered losses, have until April 14, 2026, to request to be appointed as lead plaintiff.
REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of "Moderate Buy" from Analysts
REGENXBIO Inc. (NASDAQ:RGNX) has received an average "Moderate Buy" rating from analysts, with ten brokerages covering the stock and an average 12-month target price of $27.50. Despite the positive analyst outlook, the company recently missed quarterly earnings and revenue expectations, reporting negative EPS and lower-than-anticipated revenue. Insiders and institutional investors hold significant stakes in the company, though one insider recently sold shares.
STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: LEVI & KORSINSKY, LLP
Levi & Korsinsky, LLP has announced that Stephen Pakola, REGENXBIO's Executive Vice President and Chief Medical Officer, is named as an individual defendant in a securities class action. The lawsuit alleges that Dr. Pakola made misleading statements about the safety of RGX-111 gene therapy, which led to a significant drop in RGNX shares when the truth emerged. Investors are encouraged to determine if they qualify to recover losses, with a lead plaintiff deadline of April 14, 2026.
Trading Systems Reacting to (RGNX) Volatility
The article discusses the volatility of Regenxbio Inc. (NASDAQ: RGNX) and provides an AI-driven analysis. It highlights divergent sentiment and elevated downside risk, offering three distinct trading strategies (Position Trading, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal insights regarding support and resistance levels.
RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO Inc. Securities Lawsuit -- The Gross Law Firm
The Gross Law Firm has issued a shareholder alert for investors of REGENXBIO Inc. (RGNX) who incurred losses during the class period of February 9, 2022, to January 27, 2026. The lawsuit alleges that REGENXBIO made misleading statements about the efficacy and safety of its RGX-111 gene therapy trial, which led to a significant stock price drop after the FDA placed a clinical hold on the therapy. Shareholders are encouraged to contact the firm by April 14, 2026, to potentially be appointed as lead plaintiff in the class action.
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX) and certain officers, alleging federal securities law violations. The lawsuit claims that REGENXBIO made false and misleading statements regarding its RGX-111 gene therapy for MPS I, overstating its efficacy and safety profile. Investors who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026, are encouraged to join the case, with an April 14, 2026, deadline to request lead plaintiff appointment.
RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO Inc. Securities Lawsuit — The Gross Law Firm
The Gross Law Firm has issued a shareholder alert for investors of REGENXBIO Inc. (NASDAQ: RGNX) who suffered losses during the class period of February 9, 2022, to January 27, 2026. The lawsuit alleges that REGENXBIO made misleading statements about its gene therapy RGX-111, which later received a clinical hold from the FDA after an adverse event, causing a significant drop in stock price. Shareholders have until April 14, 2026, to seek lead plaintiff appointment.
Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors
The Portnoy Law Firm has announced a class action lawsuit against REGENXBIO, Inc. on behalf of investors who purchased securities between February 9, 2022, and January 27, 2026. The lawsuit alleges that REGENXBIO made false and misleading statements regarding the efficacy and safety of its RGX-111 gene therapy trial, citing a clinical hold placed by the FDA after a CNS tumor was found in a study participant. Investors have until April 14, 2026, to file a lead plaintiff motion.
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is reminding investors of a class action lawsuit against REGENXBIO Inc. (RGNX) for alleged securities fraud. The lawsuit claims that Regenxbio made false and misleading statements regarding its product candidate RGX-111 by concealing negative data on its efficacy and safety, leading to investor losses. Investors who purchased RGNX securities between February 9, 2022, and January 27, 2026, are encouraged to contact the firm before April 14, 2026, to potentially lead the lawsuit.
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX), alleging that the company made materially false and misleading statements regarding its gene therapy RGX‑111 for Hurler syndrome. Investors who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026, are encouraged to join the lawsuit to recover damages by April 14, 2026. The firm operates on a contingency fee basis, seeking reimbursement only if successful.
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of REGENXBIO Inc. to Contact the Firm Today!
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against REGENXBIO Inc. (NASDAQ:RGNX) and certain officers for alleged violations of federal securities laws. The lawsuit claims that REGENXBIO made materially false and misleading statements regarding its RGX‑111 gene therapy for Hurler syndrome. Investors who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026, are encouraged to contact the firm to potentially join the case and request to be appointed as lead plaintiff by April 14, 2026.
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit
Rosen Law Firm reminds investors who purchased REGENXBIO, Inc. (NASDAQ: RGNX) securities between February 9, 2022, and January 27, 2026, of the April 14, 2026 lead plaintiff deadline in a securities fraud lawsuit. The lawsuit alleges that REGENXBIO made misleading statements regarding its RGX-111 gene therapy trial, concealing adverse facts about its efficacy and safety. Investors who suffered damages are encouraged to contact Rosen Law Firm to join the class action.
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is reminding investors of a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX) for alleged securities fraud. The lawsuit claims Regenxbio made misleading statements about its product candidate RGX-111, concealing negative efficacy and safety data, including the discovery of a CNS tumor in a study participant. Investors who purchased securities between February 9, 2022, and January 27, 2026, are encouraged to contact the firm by April 14, 2026, to participate in the lawsuit and recover their losses.
RGNX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO Investors of Securities Class Action Deadline on April 14, 2026
Faruqi & Faruqi, LLP is investigating potential claims against REGENXBIO Inc. (NASDAQ: RGNX) and reminds investors of the April 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that REGENXBIO made false and misleading statements regarding the efficacy and safety of its RGX-111 trial study, after the FDA placed a clinical hold on its investigational gene therapy following a reported neoplasm in a participant. Investors who suffered losses between February 9, 2022, and January 27, 2026, are encouraged to contact the firm.
RGNX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO Investors of Securities Class Action Deadline on April 14, 2026
Faruqi & Faruqi, LLP is reminding REGENXBIO (NASDAQ: RGNX) investors of the April 14, 2026 deadline to serve as lead plaintiff in a federal securities class action. The lawsuit alleges that REGENXBIO made misleading statements regarding the efficacy and safety of its RGX-111 trial study, leading to a significant stock price drop after the FDA placed a clinical hold on RGX-111 and RGX-121 due to a reported neoplasm. Investors who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026, and suffered losses are encouraged to contact the firm.
RGNX Stockholders Have Opportunity to Lead REGENXBIO Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against REGENXBIO Inc. (NASDAQ:RGNX) for alleged federal securities law violations. The lawsuit claims REGENXBIO made materially false and misleading statements regarding its RGX-111 gene therapy development and commercialization, particularly concerning its efficacy and safety profile. Investors who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026, are encouraged to join the lawsuit, with a lead plaintiff deadline of April 14, 2026.
Vanguard (RGNX) disaggregates holdings; reports 0 shares after realignment
The Vanguard Group has filed an Amendment No. 10 to its Schedule 13G/A report, indicating that it now beneficially owns 0 shares of REGENXBIO Inc. (RGNX) common stock, representing 0% of the class. This change is due to an internal realignment on January 12, 2026, which resulted in certain Vanguard subsidiaries and business divisions reporting their beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. As a result, Vanguard no longer includes these holdings in its own reported beneficial ownership.
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has announced a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX) and its officers. The lawsuit alleges that REGENXBIO made false and misleading statements regarding the development and commercialization of RGX‑111, a gene therapy for severe MPS I, during the period of February 9, 2022, to January 27, 2026. Investors who suffered losses are encouraged to join the case by April 14, 2026, to potentially be appointed as lead plaintiff.
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against REGENXBIO Inc. on behalf of investors who purchased securities between February 9, 2022, and January 27, 2026. The lawsuit alleges that REGENXBIO made false and misleading statements regarding its RGX-111 gene therapy for Hurler syndrome. Investors have until April 14, 2026, to request to be appointed as lead plaintiff.
REGENXBIO Inc. $RGNX Shares Purchased by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. significantly increased its stake in REGENXBIO Inc. by 64.5% in the fourth quarter, now holding 2.29% of the company's shares. Despite this increased institutional interest, REGENXBIO recently missed quarterly earnings expectations, reporting a wider loss and lower revenue than estimated. Analysts currently have a "Moderate Buy" consensus rating for RGNX, with an average price target of $27.50, significantly above its current trading price of around $8.26.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX
Pomerantz LLP has filed a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX) on behalf of investors who suffered losses. The lawsuit was prompted by a significant drop in Regenxbio's stock price after the FDA placed a clinical hold on two of its investigational gene therapies, RGX-111 and RGX-121, due to a reported neoplasm in a participant and similarities between the products. Investors have until April 14, 2026, to apply to be appointed as Lead Plaintiff.
ROSEN, NATIONAL TRIAL LAWYERS, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
The Rosen Law Firm is encouraging investors of REGENXBIO, Inc. (NASDAQ: RGNX) to secure counsel before the April 14, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that REGENXBIO made false and misleading statements regarding the efficacy and safety of its RGX-111 gene therapy trial during the period of February 9, 2022, to January 27, 2026. Investors who purchased securities during this period may be entitled to compensation.
ROSEN, NATIONAL TRIAL LAWYERS, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before ...
The Rosen Law Firm is encouraging REGENXBIO, Inc. investors who purchased securities between February 9, 2022, and January 27, 2026, to secure legal counsel before the April 14, 2026, lead plaintiff deadline. The firm alleges that REGENXBIO provided misleading information about the development and commercialization of its product candidate, RGX-111, leading to investor damages when the true details came to light. Investors can contact the Rosen Law Firm for more information on joining the class action lawsuit.
ROSEN, NATIONAL TRIAL LAWYERS, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
The Rosen Law Firm is encouraging investors of REGENXBIO, Inc. (NASDAQ: RGNX) who purchased securities between February 9, 2022, and January 27, 2026, to secure counsel before the April 14, 2026, lead plaintiff deadline for a securities class action. The lawsuit alleges that REGENXBIO made false and misleading statements regarding the efficacy and safety of its RGX-111 gene therapy trial. Investors who suffered damages may be entitled to compensation.
RGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX) and its officers, inviting shareholders who incurred losses between February 9, 2022, and January 27, 2026, to join. The lawsuit alleges that REGENXBIO made false and misleading statements about the development and commercialization of RGX‑111, a gene therapy for MPS I, and overstated its efficacy and safety profile. Investors have until April 14, 2026, to request to be appointed lead plaintiff.
SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD
Institutional investors holding REGENXBIO, Inc. (RGNX) stock between February 9, 2022, and January 27, 2026, are advised to evaluate lead plaintiff opportunities in a securities class action lawsuit. The lawsuit alleges that REGENXBIO made misleading statements about the safety of its RGX-111 gene therapy after the FDA placed a clinical hold on the program due to a CNS tumor in a trial participant, leading to a significant stock price decline. SUEWALLST, LLP encourages institutional investors to assess their recovery options and potential role as lead plaintiff.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX
Pomerantz LLP has filed a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX) for alleged securities fraud, following a significant stock drop when the FDA placed a clinical hold on two of its gene therapies. Investors who purchased Regenxbio securities during the Class Period have until April 14, 2026, to seek lead plaintiff status. The lawsuit stems from an announcement that the FDA halted trials for RGX-111 and RGX-121 due to a reported neoplasm in a participant.
SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD
SUEWALLST, LLP is alerting institutional investors of potential portfolio losses from alleged fraud concerning REGENXBIO (NASDAQ: RGNX) and its RGX-111 gene therapy program. A class action lawsuit has been filed, asserting that REGENXBIO made misleading statements about the therapy's safety, leading to an 17.8% stock decline after a CNS tumor finding and FDA clinical hold. Institutional holders with fiduciary duties are encouraged to evaluate their recovery options and consider applying for lead plaintiff appointment by April 14, 2026.
SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD
SUEWALLST, LLP has issued a notice alerting institutional investors holding REGENXBIO (RGNX) shares between February 9, 2022, and January 27, 2026, about potential portfolio losses due to alleged gene therapy fraud. The firm suggests these investors evaluate lead plaintiff opportunities in a pending securities class action. The lawsuit claims REGENXBIO made misleading statements regarding the safety of its RGX-111 gene therapy, leading to a 17.8% stock decline after an FDA clinical hold related to CNS tumor discovery.
Denali Jumps, Pulling Regenxbio Higher, On Early FDA Approval
Denali Therapeutics received early FDA approval for a new drug to treat Hunter syndrome, a rare genetic disease affecting children, marking the first new treatment in 20 years. This approval, coming nearly two weeks ahead of schedule, caused Denali's stock to jump and also pulled up Regenxbio, despite the latter's gene therapy for the same condition being rejected by the FDA a month prior.
RGNX's Inadequate Risk Disclosures Allegedly Cost Investors $2.40/Share: Levi & Korsinsky, LLP
Levi & Korsinsky, LLP is investigating REGENXBIO, Inc. (NASDAQ: RGNX) for allegedly inadequate risk disclosures to investors between February 9, 2022, and January 27, 2026. The lawsuit claims REGENXBIO shareholders lost $2.40 per share after an FDA clinical hold on RGX-111, stemming from an intraventricular CNS tumor linked to AAV vector genome integration, which the company allegedly failed to disclose despite awareness of oncogenic risks. Investors have until April 14, 2026, to seek lead plaintiff status in the class action.
RGNX Shareholder Alert: April 14, 2026 Lead Plaintiff Deadline in REGENXBIO Inc. Securities Class Action Lawsuit -- The Gross Law Firm
The Gross Law Firm has announced a shareholder alert for REGENXBIO Inc. (NASDAQ: RGNX) investors, setting an April 14, 2026, lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that REGENXBIO made false and misleading statements regarding its gene therapy RGX-111, which later received a clinical hold from the FDA due to an adverse event, leading to a significant stock price drop. Shareholders who purchased RGNX shares between February 9, 2022, and January 27, 2026, are encouraged to register.
RGNX's Inadequate Risk Disclosures Allegedly Cost Investors $2.40/Share: Levi & Korsinsky, LLP
Levi & Korsinsky, LLP is investigating Regenxbio Inc. (RGNX) regarding potential breaches of fiduciary duty and violations of securities laws. The investigation arises from allegations that Regenxbio made inadequate disclosures concerning the risks associated with its gene therapy treatment, ABBV-RGX-314, for wet age-related macular degeneration (wet AMD). These alleged disclosure failures led to a significant stock drop, reportedly costing investors $2.40 per share.
